However, ER access and ERAD-mediated processing of GRP170–antigen complex in the setting of therapeutic vaccination warrant more studies, which will result in a better understanding of the action of this molecular adjuvant and the optimization of GRP170-based targeted cancer vaccination strategies. Here, HYOU1 is linked to cancer.